U-M ChE associate professor, Greg Thurber, has been recognized with the George R. Pettit Individual Input to the Field Award. He was presented with the award at the 2021 World Antibody Drug Conjugate (World ADC) Conference.
Greg Thurber, U-M Chemical Engineering associate professor, has been recognized with the George R. Pettit Individual Input to the Field Award. He was presented with the award at the 2021 World Antibody Drug Conjugate (World ADC) Conference. Thurber is also the first recipient of the award after it was renamed in honor of the prolific George R. Pettit.
“It is a great honor to receive this award in the field of ADCs (antibody drug conjugates), which was just named in memory of the pioneering chemist, George R. Pettit,” said Thurber. “After many years of challenges, the field has undergone tremendous growth, almost tripling the number of approved drugs in 3 years, and I look forward to continuing our work and collaborations to get more of these life-saving drugs on the market.”
“After many years of challenges, the field has undergone tremendous growth, almost tripling the number of approved drugs in 3 years, and I look forward to continuing our work and collaborations to get more of these life-saving drugs on the market.”
Greg Thurber
Associate Professor, U-M Chemical Engineering
The World ADC Awards seek to recognize excellence within antibody-drug conjugate research, particularly those who push the boundaries in the pursuit of fighting cancer. Across nine categories and eleven awards, World ADC hopes to showcase, on a global scale, the extraordinary endeavors, teamwork, and commercial understanding which has propelled antibody-drug research to the forefront of cancer research.
George R. Pettit is renowned for his contributions to anti-cancer drugs over the course of his 55-year career at Arizona State University. He assembled a portfolio of over 800 peer-reviewed publications and 14 books in addition to nearly 70 patents for anti-cancer compounds.
Thurber’s research focuses heavily on treatment for cancer and other deadly diseases, such as Alzheimer’s, autoimmune disorders, and cardiovascular disease. Specifically, he looks at these issues through the lenses of molecular imaging and quantitative pharmacology to design more effective agents.
The Thurber Lab, using in vivo microscopy and mathematical simulations, seeks to develop quantitative and predictive simulation models for cancer therapy and chemoprevention. The lab is a joint venture between the departments of Chemical Engineering and Biomedical Engineering.
Greg Thurber joined the Department of Chemical Engineering at U-M in 2012. He was promoted to associate professor in 2019 and currently serves as the Associate Chair for Graduate Education. He also holds an associate professor appointment in the Department of Biomedical Engineering and is a member of the Rogel Cancer Center.
